TY - JOUR
T1 - Immunosuppression in renal cancer
T2 - Differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes
AU - Riccobon, Angela
AU - Gunelli, Roberta
AU - Ridolfi, Ruggero
AU - De Paola, Franca
AU - Flamini, Emanuela
AU - Fiori, Massimo
AU - Saltutti, Carlo
AU - Petrini, Massimiliano
AU - Fiammenghi, Laura
AU - Stefanelli, Monica
AU - Granato, Anna Maria
AU - Cuzzocrea, Diego Ettore
AU - Amadori, Dino
PY - 2004
Y1 - 2004
N2 - Alterations in the expression of signal activation molecules, such as the T-cell receptor (TCR) ζ and ε chains and p56lck tyrosine kinase, are described in tumor-infiltrating lymphocytes (TIL). The aim of this study was to ascertain if such molecules were present in near-tumor-tissue lmphocytes (NTTL) and peripheral blood lymphocytes (PBL), as well as TIL, of renal cell carcinoma patients, to verify whether this tumor induces immunosuppression only locally or affects distant lymphocytes as well. Tissue from the tumor and from healthy nearby sites, as well as blood samples, were obtained from 27 consecutive patients who had undergone radical nephrectomy for renal cell carcinoma. Phenotype analysis and immunohistochemical staining of the TCR ζ and ε chains and p56lck were performed with standard techniques on TIL, NTTL, and PBL, and values were compared for each patient. Low expression of the TCR ζ chain and an almost complete absence of TCR ε chain and p56lck expression was observed in TIL (median values: 10% for ζ chain and 0% for ε and p56lck). In NTTL, these signal transduction molecules were expressed by a higher percentage of cells (60%, 50%, and 60%, respectively; p=0.000 vs. TIL), whereas PBL showed an almost normal expression of ζ and ε chains (80% and 90%, respectively; p=0.000 vs. TIL). Conversely, p56lck was detected in a greater proportion of NTTL than PBL (50% vs. 10%; p=0.001). The absence or the very low expression of signaling activation molecules in TIL compared with NTTL and PBL in renal cancer patients suggest that tumor-induced immunosuppression generally occurs or starts locally.
AB - Alterations in the expression of signal activation molecules, such as the T-cell receptor (TCR) ζ and ε chains and p56lck tyrosine kinase, are described in tumor-infiltrating lymphocytes (TIL). The aim of this study was to ascertain if such molecules were present in near-tumor-tissue lmphocytes (NTTL) and peripheral blood lymphocytes (PBL), as well as TIL, of renal cell carcinoma patients, to verify whether this tumor induces immunosuppression only locally or affects distant lymphocytes as well. Tissue from the tumor and from healthy nearby sites, as well as blood samples, were obtained from 27 consecutive patients who had undergone radical nephrectomy for renal cell carcinoma. Phenotype analysis and immunohistochemical staining of the TCR ζ and ε chains and p56lck were performed with standard techniques on TIL, NTTL, and PBL, and values were compared for each patient. Low expression of the TCR ζ chain and an almost complete absence of TCR ε chain and p56lck expression was observed in TIL (median values: 10% for ζ chain and 0% for ε and p56lck). In NTTL, these signal transduction molecules were expressed by a higher percentage of cells (60%, 50%, and 60%, respectively; p=0.000 vs. TIL), whereas PBL showed an almost normal expression of ζ and ε chains (80% and 90%, respectively; p=0.000 vs. TIL). Conversely, p56lck was detected in a greater proportion of NTTL than PBL (50% vs. 10%; p=0.001). The absence or the very low expression of signaling activation molecules in TIL compared with NTTL and PBL in renal cancer patients suggest that tumor-induced immunosuppression generally occurs or starts locally.
KW - p56
KW - Renal cell carcinoma
KW - TCR ζ chain
KW - Tumor-infiltrating lymphocytes (TIL)
UR - http://www.scopus.com/inward/record.url?scp=10844229511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10844229511&partnerID=8YFLogxK
U2 - 10.1081/CNV-200039653
DO - 10.1081/CNV-200039653
M3 - Article
C2 - 15641485
AN - SCOPUS:10844229511
VL - 22
SP - 871
EP - 877
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 6
ER -